Tadalafil for Treatment of Pulmonary Hypertension: Mechanisms, Evidence, and Emerging Perspectives
Abstract
Pulmonary arterial hypertension (PAH), a subset of pulmonary hypertension (PH), remains a progressive and debilitating disease marked by vascular remodeling and elevated pulmonary vascular resistance. Tadalafil, a phosphodiesterase type 5 inhibitor (PDE-5i), plays a central role in the nitric oxide-cyclic guanosine monophosphate pathway, enhancing vasodilation and reducing right ventricular afterload. Compared with sildenafil, tadalafil offers the advantages of once-daily dosing, a longer half-life, and favorable tolerability. A randomized controlled trial and its long-term extension demonstrated significant improvements in 6-minute walk distance, functional class, and hemodynamic parameters in patients with PAH, with sustained efficacy and an acceptable safety profile over time. Current international guidelines recommend tadalafil both as monotherapy and in combination regimens, particularly with endothelin receptor antagonists like ambrisentan, for World Health Organization functional class (WHO-FC) II or III PAH patients. Beyond PAH, tadalafil's therapeutic potential in WHO Group 2 PH, especially in heart failure with preserved ejection fraction, has been investigated with mixed results. While preclinical models suggest benefits in left ventricular function and remodeling, the PASSION (Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction) trial in heart failure with…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- 2024 update in heart failure
- An Eco-Friendly Solid-State Electrode Modified With ZnO Nanoparticles Decorated With MWCNT as an Electrochemical Sensor for the Determination of Avanafil in Pure Form, Dosage Form and Human Plasma
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.